Natalizumab Treatment in Multiple Sclerosis

Clinical Neurology - Japan
doi 10.5692/clinicalneurol.cn-000690
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Societas Neurologica Japonica

Related search

Natalizumab Versus Fingolimod and Dimethyl Fumarate in Multiple Sclerosis Treatment

Annals of Clinical and Translational Neurology
NeuroscienceNeurology
2018English

Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
Chemical HealthPharmacologySafetyMedicineToxicologySafety ResearchPharmaceutics
2007English

Clinical Effects of Natalizumab on Multiple Sclerosis Appear Early in Treatment Course

Journal of Neurology
Neurology
2013English

Natalizumab Therapy for Highly Active Pediatric Multiple Sclerosis

JAMA Neurology
Neurology
2013English

Alemtuzumab Following Natalizumab in Highly Active Paediatric-Onset Multiple Sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical
2019English

Pregnancy Decision-Making in Women With Multiple Sclerosis Treated With Natalizumab

Neurology
Neurology
2020English

Evolution of MRI Appearances Due to Progressive Multifocal Leucoencephalopathy Following Natalizumab Treatment for Multiple Sclerosis

BMJ Case Reports
Medicine
2015English

Pnd39 Multiple Sclerosis Patients Report Improvements in Fatigue and Cognitive Functioning After One Year of Natalizumab Treatment

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation

PLoS ONE
Multidisciplinary
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy